Financial results
Zentia Reports Third Quarter 2026 Financial Results and Business Updates
Company progress on the ASPENOVA Phase 3 program and continued enrollment across late-stage trials.
News & events
Zentia spotlight
Financial results, clinical milestones and conference presentations — the latest from across the company.
Financial results
August 12, 2026
Q3 2026: strong progress across the ASPENOVA Phase 3 program
Enrollment continues across global sites, with operating guidance updated following the advancement of our registration-intent programs.
Read the releaseAll news
Latest headlines
Clinical trial
First Patient Dosed in the ASPENOVA Phase 3 Trial in Cyclin E1-Positive Ovarian Cancer
Global enrollment begins for the first oral, biomarker-driven approach in this patient population.
Conference
Zentia to Present New Clinical Data at the ESMO Congress 2026
Updated safety and efficacy data from our ongoing clinical programs will be featured this year.
Clinical trial
Phase 2 Data Support Biomarker-Defined Strategy in Uterine Serous Carcinoma
Updated findings reinforce the companion diagnostic and registration-intent design.
Corporate
Zentia Expands Manufacturing Partnership for Oral Formulation
New supply agreement supports commercial readiness as late-stage programs advance.
Financial results
Zentia Provides Full-Year 2025 Financial Results and 2026 Outlook
Capital position expected to fund operations through key registration milestones.
Conference
Zentia to Present at the J.P. Morgan Healthcare Conference
Executive team to discuss pipeline progress and 2026 priorities with investors.